About Intercept Pharmaceuticals
Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.
Intercept's lead compound, INT-747, is a modified human bile acid and first-in-class FXR agonist that is currently in Phase II testing. Clinical proof of concept was recently demonstrated in a Phase II, placebo-controlled trial of INT-747 in type 2 diabetics with fatty liver disease. Based on these results, the company plans to advance INT-747 in a Phase IIb trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. INT-747 is completing two additional Phase II trials in patients with primary biliary cirrhosis, an autoimmune cholestatic liver disease and orphan indication. Results from the first of the two studies are expected in the fourth quarter of 2009.
INT-777 is a modified human bile acid and selective TGR5 agonist that is currently being assessed in IND-enabling studies.
|SOURCE Intercept Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved